Onyx & Bayer Ink Pact for Regorafenib

Onyx and Bayer HealthCare have entered into a new agreement for Bayer’s regorafenib, a late-stage oncology compound.

California-based biopharmaceutical company Onyx Pharmaceuticals and Bayer HealthCare have restructured their partnership for the global development and marketing of Nexavar (sorafenib) tablets, and inked a new deal for Bayer’s regorafenib, a late-stage oncology compound.

 
Bayer will have the final say for global development and commercialization of regorafenib and Onyx will receive a royalty on any future global sales in oncology. Both companies will promote regorafenib in the U.S. 

Under the revised Nexavar collaboration, Onyx and Bayer are free to use their respective Nexavar sales forces to promote regorafenib and additional products outside of the collaboration in the future. Bayer will purchase Onyx's royalty rights for sale